What question did this study set out to answer?

This research aims to assess the safety and efficacy of HPK1 inhibitor NDI-101150, both alone and in combination with pembrolizumab, in patients with advanced solid tumors.

May 10, 2026Cell Reports MedicineOpen Access

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results

View Full Paper

Ask AI

Bookmark

This research aims to assess the safety and efficacy of HPK1 inhibitor NDI-101150, both alone and in combination with pembrolizumab, in patients with advanced solid tumors.
Phase 1/2 trial design
Involves treatment with NDI-101150 and potential combination with pembrolizumab
Clinical registration number NCT05128487
Evaluation of T cell and dendritic cell interactions in the tumor microenvironment (TME)
Promising signals for continued drug development in treating advanced solid tumors

Implication

Randomized trial evaluates the effectiveness of HPK1 inhibitor and pembrolizumab in advanced solid tumors, suggesting new treatment options.

Abstract

T cells and dendritic cells in the TME, supporting continued development (clinical registration number NCT05128487).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Braun et al. (2026) studied this question.

synapsesocial.com/papers/6a001ff2c8f74e3340f9b21f https://doi.org/10.1016/j.xcrm.2026.102789

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates the effectiveness of HPK1 inhibitor and pembrolizumab in advanced solid tumors, suggesting new treatment options.

Abstract

T cells and dendritic cells in the TME, supporting continued development (clinical registration number NCT05128487).

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results

Key Points

Implication

Abstract

Discussion

Cite This Study

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading